AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11299576 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating pressure air mattress A
Number of subjects: 0
Study 11299576 — intervention group
Group type: COMPARATOR
Intervention: Alternating pressure air mattress B
Number of subjects: 0
Study 8635384 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin 50 mg/m2 or 100 mg/m2 plus 3 g/m2 ifosfamide and 6 mg/m2 mitomycin)
Number of subjects: 0
Study 8635384 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 8635384 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of genetic alterations
Number of subjects: 0
Study 30652260 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label topical therapies (e.g., prostaglandin analogs, polyphenols like latanoprost and procyanidin oligomers)
Number of subjects: 16
Study 30652260 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyanidin oligomers
Number of subjects: 16
Study 30652260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28722284 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiglide 2 guidewire (group V)
Number of subjects: 100
Study 28722284 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidewire (group C)
Number of subjects: 100
Study 26684457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib sodium 1 mg·kg(‐1) (Group P, n = 30)
Number of subjects: 60
Study 26684457 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S, n = 30)
Number of subjects: 60
Study 26684457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib sodium 1 mg·kg(‐1) (Group P)
Number of subjects: 60
Study 26684457 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 60
Study 25238838 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treadmill training (16-week program, 3 sessions/week, 30-40 min treadmill exercise at 60-75% peak heart rate)
Number of subjects: 60
Study 25238838 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study 22186009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g)
Number of subjects: 73
Study 22186009 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 73
Study 18974283 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 50 mg/mL and 20 mg/mL formulations
Number of subjects: 64
Study 18974283 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 50 mg/mL formulation
Number of subjects: 64
Study 18974283 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 20 mg/mL formulation (1.0 mL)
Number of subjects: 64
Study 18974283 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide treatments
Number of subjects: 64
Study 18974283 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site pain
Number of subjects: 64
Study 16988133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (20,000 IU for <12 months; 45,000 IU for >=12 months) every 2 months
Number of subjects: 127
Study 16988133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in children infected with enteropathogenic Escherichia coli (EPEC)
Number of subjects: 127
Study 16988133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in children not infected with Ascaris lumbricoides
Number of subjects: 127
Study 16988133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 12802915 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 101
Study 12802915 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study 10866887 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.0 microg/kg/min
Number of subjects: 8
Study 10866887 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.33 microg/kg/min
Number of subjects: 8
Study 10866887 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.2 microg/kg/min
Number of subjects: 8
Study 15622781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 100
Study 15622781 — intervention group
Group type: COMPARATOR
Intervention: Control group (without CsA)
Number of subjects: 100
Study 8225624 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (2 g)
Number of subjects: 595
Study 8225624 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (2.2 g)
Number of subjects: 595
Study 3535004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 38
Study 3535004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3535004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 38
Study 3535004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (R)
Number of subjects: 38
Study 3535004 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (NR)
Number of subjects: 38
Study 31663980 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcribed list of six treatment recommendations
Number of subjects: 72
Study 31663980 — intervention group
Group type: COMPARATOR
Intervention: Verbal discussion of six treatment recommendations
Number of subjects: 72
Study 28537508 — intervention group
Group type: EXPERIMENTAL
Intervention: LALC
Number of subjects: 105
Study 28537508 — intervention group
Group type: COMPARATOR
Intervention: CLC
Number of subjects: 105
Study 28537508 — intervention group
Group type: COMPARATOR
Intervention: SILC
Number of subjects: 105
Study 27179104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 27179104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24952869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg intraoperatively)
Number of subjects: 822
Study 24952869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 22885981 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25g polydextrose
Number of subjects: 34
Study 22885981 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5g polydextrose
Number of subjects: 34
Study 22885981 — intervention group
Group type: COMPARATOR
Intervention: 0g polydextrose (control)
Number of subjects: 34
Study 20634438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg every 48 hours)
Number of subjects: 434
Study 20634438 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 434
Study 18327780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector (group II, n = 21)
Number of subjects: 52
Study 18327780 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical techniques (group I, n = 31)
Number of subjects: 52
Study 17178938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin otic drops
Number of subjects: 306
Study 17178938 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin-polymyxin B otic drops
Number of subjects: 306
Study 17178938 — intervention group
Group type: COMPARATOR
Intervention: No postoperative otic drop prophylaxis (Control group)
Number of subjects: 306
Study 14574830 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg 3 times daily for 2 weeks
Number of subjects: 30
Study 14574830 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg 3 times daily for 2 weeks
Number of subjects: 30
Study 14574830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14574830 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (both dosages)
Number of subjects: 30
Study 10782522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.pt.) - D. farinae (D.f) 50/50 extract, mean cumulative dose of 90,000 IR (2.2 mg of Der p 1 and 1.7 mg of Der f I) for 24 months.
Number of subjects: 75
Study 10782522 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 24 months.
Number of subjects: 75
Study 8633933 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde warm blood cardioplegia
Number of subjects: 34
Study 8633933 — intervention group
Group type: COMPARATOR
Intervention: Standard cold topical irrigation
Number of subjects: 34
Study 1727165 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg bolus and 5.4 mg/kg/hr for 23 hours)
Number of subjects: 0
Study 1727165 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (5.4 mg/kg bolus and 4.0 mg/kg/hr for 23 hours)
Number of subjects: 0
Study 1727165 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone or Naloxone
Number of subjects: 0
Study 6376653 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent streptococcus pneumoniae polysaccharide vaccine
Number of subjects: 1273
Study 6376653 — intervention group
Group type: COMPARATOR
Intervention: Saline as placebo
Number of subjects: 1273
Study 29439711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 330
Study 29439711 — intervention group
Group type: COMPARATOR
Intervention: Surgical liver resection
Number of subjects: 330
Study 27295927 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with immediately loaded mandibular overdenture
Number of subjects: 2
Study 27295927 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement with immediately loaded mandibular overdenture
Number of subjects: 2
Study 25428140 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for ADHD symptoms and IPV, duration of treatment is one year with assessments at t0, 8, 16, 24, and 52 weeks.
Number of subjects: 0
Study 24341093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin sodium iv at 1.0 g 30 minutes before complete urodynamic examination
Number of subjects: 256
Study 24341093 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment (Control)
Number of subjects: 256
Study 20026265 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/d
Number of subjects: 1489
Study 20026265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1489
Study 18084691 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg daily oral DHEA supplementation for one year
Number of subjects: 225
Study 16810592 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 100
Study 16810592 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus pethidine
Number of subjects: 100
Study 12754879 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 500000
Study 11140880 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu23F2G
Number of subjects: 0
Study 11140880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9344324 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin or epirubicin
Number of subjects: 0
Study 9344324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 0
Study 9344324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Number of subjects: 0
Study 9344324 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-ifosfamide combination chemotherapy
Number of subjects: 0
Study 1416422 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% O2
Number of subjects: 12
Study 1416422 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 12
Study 3927763 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 7.5 micrograms/kg
Number of subjects: 20
Study 3927763 — intervention group
Group type: COMPARATOR
Intervention: fentanyl 1.5 micrograms/kg
Number of subjects: 20
Study 31375613 — intervention group
Group type: EXPERIMENTAL
Intervention: CCKO intervention (dedicated key workers and coordinated shared care plans)
Number of subjects: 0
Study 31375613 — intervention group
Group type: EXPERIMENTAL
Intervention: CCKO intervention
Number of subjects: 0
Study 31375613 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 28295802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy based on the Clark and Wells model
Number of subjects: 46
Study 28295802 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in metacognitive beliefs
Number of subjects: 46
Study 28295802 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cognitive beliefs
Number of subjects: 46
Study 28295802 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in self-consciousness
Number of subjects: 46
Study 28295802 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in metacognition
Number of subjects: 46
Study 26045397 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Imagery (VI)
Number of subjects: 24
Study 26045397 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic Imagery (KI)
Number of subjects: 24
Study 26045397 — intervention group
Group type: COMPARATOR
Intervention: Mental Arithmetic Task (MAT)
Number of subjects: 24
Study 24290734 — intervention group
Group type: EXPERIMENTAL
Intervention: LEP-ETU (liposome-entrapped paclitaxel)
Number of subjects: 58
Study 24290734 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel formulated with polyethoxylated castor oil (reference)
Number of subjects: 58
Study 21508389 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX treatment (capecitabine plus oxaliplatin) with bevacizumab
Number of subjects: 81
Study 20112562 — intervention group
Group type: EXPERIMENTAL
Intervention: Poking reduction
Number of subjects: 80
Study 20112562 — intervention group
Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 80
Study 16669956 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen enema (240 mg daily for 6 weeks)
Number of subjects: 112
Study 16669956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 15571956 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for three months followed by 1 mg daily for five years
Number of subjects: 24
Study 11256555 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (270 microg four times daily) for 2 weeks
Number of subjects: 11
Study 11256555 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 2 weeks of inhaled albuterol
Number of subjects: 11
Study 11256555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9143863 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.0‐2.0 mg.day‐1) for 2‐13 years
Number of subjects: 31
Study 9143863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous colchicine (2 mg) infusion
Number of subjects: 31
Study 9143863 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 5)
Number of subjects: 31
Study 7960013 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilting in hypertensive subjects
Number of subjects: 40
Study 7960013 — intervention group
Group type: COMPARATOR
Intervention: Head-up tilting in control subjects
Number of subjects: 40
Study 7960013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency components in systolic blood pressure after tilting in hypertensive subjects
Number of subjects: 40
Study 7960013 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency components in systolic blood pressure after tilting in control subjects
Number of subjects: 40
Study 7960013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency components in skin blood flow after tilting in hypertensive subjects
Number of subjects: 40
Study 7960013 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency components in skin blood flow after tilting in control subjects
Number of subjects: 40
Study 7960013 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity in hypertensive subjects
Number of subjects: 40
Study 7960013 — intervention group
Group type: COMPARATOR
Intervention: Baroreflex sensitivity in control subjects
Number of subjects: 40
Study 3591854 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (frequency of exercise not specified)
Number of subjects: 141
Study 3591854 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 141
Study 31034030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoon warmer (CW)
Number of subjects: 125
Study 31034030 — intervention group
Group type: COMPARATOR
Intervention: Radiant warmer (RW)
Number of subjects: 125
Study 30449513 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-stage duodenal switch (DS)
Number of subjects: 118
Study 30449513 — intervention group
Group type: COMPARATOR
Intervention: Single-stage laparoscopic biliopancreatic diversion with duodenal switch (BPD-DS)
Number of subjects: 118
Study 30449513 — intervention group
Group type: COMPARATOR
Intervention: First-stage biliopancreatic diversion with duodenal switch (BPD-DS)
Number of subjects: 118
Study 26741384 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Ultra (24 mg/mL)
Number of subjects: 104
Study 26741384 — intervention group
Group type: COMPARATOR
Intervention: Restylane (20 mg/mL)
Number of subjects: 104
Study 25335781 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin intake (271 mg and 7.11 mg C3g eq) in S2 trial
Number of subjects: 131
Study 25335781 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin intake (346 mg C3g eq) in L1 trial
Number of subjects: 131
Study 25335781 — intervention group
Group type: COMPARATOR
Intervention: Placebo in S2 trial
Number of subjects: 131
Study 25335781 — intervention group
Group type: COMPARATOR
Intervention: Placebo in L1 trial
Number of subjects: 131
Study 23789738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided femoral nerve block
Number of subjects: 110
Study 23789738 — intervention group
Group type: COMPARATOR
Intervention: Fascia iliaca compartment block
Number of subjects: 110
Study 21080967 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine EA
Number of subjects: 48
Study 21080967 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 48
Study 18207167 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 100
Study 16340726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic 133Xe SPECT
Number of subjects: 49
Study 14604144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 0
Study 14604144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-optic transillumination (FOTI)
Number of subjects: 0
Study 14604144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite-wing radiographic assessment
Number of subjects: 0
Study 14604144 — intervention group
Group type: COMPARATOR
Intervention: Direct visual inspection after tooth separation
Number of subjects: 0
Study 10965103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (CPM) 2 g i.v. every 12 h
Number of subjects: 69
Study 10965103 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g i.v. every 8 h
Number of subjects: 69
Study 8648203 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz (SW9) strain of measles vaccine
Number of subjects: 88
Study 8648203 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz (SW6) strain of measles vaccine
Number of subjects: 88
Study 8648203 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) strain of measles vaccine
Number of subjects: 88
Study 1442917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan, 2 gm intravenously every 12 hours
Number of subjects: 140
Study 1442917 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin, 2 gm intravenously every 6 hours
Number of subjects: 140
Study 6308068 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (20 mg b.i.d.)
Number of subjects: 14
Study 6308068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg b.i.d.)
Number of subjects: 14
Study 6308068 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (20 mg b.i.d.) and Hydrochlorothiazide (25 mg b.i.d.) in combination
Number of subjects: 14
Study 6308068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30287097 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Number of subjects: 1982
Study 30287097 — intervention group
Group type: COMPARATOR
Intervention: Saline Solution
Number of subjects: 1982
Study 30587084 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tRNS (12 min)
Number of subjects: 40
Study 30587084 — intervention group
Group type: COMPARATOR
Intervention: Sham tRNS
Number of subjects: 40
Study 30587084 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tRNS
Number of subjects: 40
Study 26558729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX)
Number of subjects: 2180
Study 26558729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2180
Study 24518149 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm for measuring medial temporal lobe (MTL) volume
Number of subjects: 150
Study 24518149 — intervention group
Group type: COMPARATOR
Intervention: FreeSurfer segmentation tools
Number of subjects: 150
Study 19342396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg daily
Number of subjects: 50
Study 19342396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15133294 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon therapy
Number of subjects: 0
Study 15133294 — intervention group
Group type: COMPARATOR
Intervention: Thermal therapy
Number of subjects: 0
Study 12575588 — intervention group
Group type: EXPERIMENTAL
Intervention: TWP combined with MT (TWP 10 mg orally, 3 times a day; MT 7.5 mg orally once a week)
Number of subjects: 70
Study 12575588 — intervention group
Group type: COMPARATOR
Intervention: MT (15 mg orally, once every week)
Number of subjects: 70
Study 12575588 — intervention group
Group type: EXPERIMENTAL
Intervention: TWP combined with MT
Number of subjects: 70
Study 12575588 — intervention group
Group type: COMPARATOR
Intervention: Control group (MT only)
Number of subjects: 70
Study 9782544 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 9
Study 9782544 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 9
Study 9782544 — intervention group
Group type: COMPARATOR
Intervention: Anti-gravity suit (anti-G)
Number of subjects: 9